Seikagaku Ceases Development of Enthesopathy Application

Seikagaku and Kaken Pharmaceutical will discontinue development of SI-657, an additional indication of enthesopathy for the ARTZ injectable joint function-improving agent. Kaken is sales partner of ARTZ in Japan.

Enthesopathy refers to a disorder involving the attachment of a tendon or ligament to bone.

The co-development project ends...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us